 |
 |

Treatment of Cryptosporidiosis With ParomomycinA Report of Five Cases
Keith Armitage, MD;
Timothy Flanigan, MD;
John Carey, MD;
Ian Frank, MD;
Rob Roy MacGregor, MD;
Paul Ross, MD;
Richard Goodgame, MD;
John Turner, MD
Arch Intern Med. 1992;152(12):2497-2499.
Abstract
Cryptosporidiosis continues to be one of the most devastating complications of the acquired immunodeficiency syndrome, causing severe, chronic diarrhea that is largely refractory to treatment. More than 60 drugs have been tried in the treatment of cryptosporidiosis, none of which have been consistently successful. We describe the successful treatment of cryptosporidiosis in five patients with acquired immunodeficiency syndrome with oral paromomycin at a dose of 1500 to 2000 mg/d. All five patients had resolution of symptoms and normalization of bowel movements, although one patient later relapsed while receiving paromomycin. Three of five patients cleared Cryptosporidium from the stool. Paromomycin is a promising therapy for cryptosporidiosis in acquired immunodeficiency syndrome and further prospective clinical trials are warranted.
(Arch Intern Med. 1992;152:2497-2499)
Author Affiliations
From the Department of Medicine, University Hospitals, Cleveland, Ohio (Dr Armitage); Department of Medicine, Miriam Hospital, Providence, RI (Dr Flanigan); Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia (Drs Frank and MacGregor); Department of Medicine, Baylor College of Medicine, Houston, Tex (Drs Ross and Goodgame; and the Department of Medicine, The Graduate Hospital, Philadelphia, Pa (Dr Turner).
Footnotes
Accepted for publication April 10, 1992.
Reprint requests to the Department of Medicine, Brown University, Miriam Hospital, 164 Summit Ave, Providence, Rl 02906 (Dr Flanigan).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Dicyclic and Tricyclic Diaminopyrimidine Derivatives as Potent Inhibitors of Cryptosporidium parvum Dihydrofolate Reductase: Structure-Activity and Structure-Selectivity Correlations
Nelson and Rosowsky
Antimicrob. Agents Chemother. 2001;45:3293-3303.
ABSTRACT
| FULL TEXT
Correction of the Hyper-IgM Syndrome after Liver and Bone Marrow Transplantation
Hadzic et al.
NEJM 2000;342:320-324.
FULL TEXT
|